

# Andrew W Roberts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5908906/publications.pdf>

Version: 2024-02-01

236  
papers

25,474  
citations

9756

73  
h-index

6979

154  
g-index

238  
all docs

238  
docs citations

238  
times ranked

24846  
citing authors

#	ARTICLE	IF	CITATIONS
1	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nature Medicine</i> , 2013, 19, 202-208.	15.2	2,426
2	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	13.9	1,532
3	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. <i>Cancer Cell</i> , 2006, 10, 389-399.	7.7	1,149
4	Programmed Anuclear Cell Death Delimits Platelet Life Span. <i>Cell</i> , 2007, 128, 1173-1186.	13.5	910
5	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. <i>Nature</i> , 2016, 538, 477-482.	13.7	830
6	SOCS3 negatively regulates IL-6 signaling in vivo. <i>Nature Immunology</i> , 2003, 4, 540-545.	7.0	743
7	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. <i>Journal of Clinical Oncology</i> , 2012, 30, 488-496.	0.8	719
8	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	5.1	676
9	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	0.8	596
10	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 242-252.	9.4	588
11	Deficiency of the Hematopoietic Cell-Specific Rho Family GTPase Rac2 Is Characterized by Abnormalities in Neutrophil Function and Host Defense. <i>Immunity</i> , 1999, 10, 183-196.	6.6	513
12	RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis. <i>Cell</i> , 2014, 157, 1175-1188.	13.5	492
13	Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 1195-1200.	3.3	347
14	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1211-1223.	13.9	343
15	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. <i>Journal of Clinical Oncology</i> , 2009, 27, 1788-1793.	0.8	315
16	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14907-14912.	3.3	310
17	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. <i>Cancer Discovery</i> , 2018, 8, 1582-1597.	7.7	310
18	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2019, 9, 342-353.	7.7	306

#	ARTICLE	IF	CITATIONS
19	G-CSF: A key regulator of neutrophil production, but that's not all!. Growth Factors, 2005, 23, 33-41.	0.5	301
20	Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9324-9329.	3.3	288
21	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncology, The, 2017, 18, 230-240.	5.1	287
22	Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood, 2009, 114, 663-666.	0.6	274
23	Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. Blood, 2011, 118, 1663-1674.	0.6	262
24	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood, 2019, 134, 851-859.	0.6	259
25	SOCS3 Is a Critical Physiological Negative Regulator of G-CSF Signaling and Emergency Granulopoiesis. Immunity, 2004, 20, 153-165.	6.6	257
26	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of Clinical Oncology, 2018, 36, 1973-1980.	0.8	257
27	BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Cancer Cell, 2018, 34, 879-891.	7.7	250
28	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood, 2016, 127, 3215-3224.	0.6	242
29	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood, 2017, 130, 2392-2400.	0.6	229
30	Targeting GM-CSF in inflammatory diseases. Nature Reviews Rheumatology, 2016, 12, 37-48.	3.5	217
31	SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. Journal of Clinical Investigation, 2006, 116, 1571-1581.	3.9	184
32	Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5614-5618.	3.3	182
33	From The Cover: Suppressor screen in Mpl <sup>-/-</sup> mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6553-6558.	3.3	178
34	Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood, 2012, 119, 5807-5816.	0.6	168
35	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. Journal of Experimental Medicine, 2011, 208, 2017-2031.	4.2	162
36	Granulocyte colony-stimulating factor and neutrophils' forgotten mediators of inflammatory disease. Nature Clinical Practice Rheumatology, 2006, 2, 500-510.	3.2	161

#	ARTICLE	IF	CITATIONS
37	Role of the Guanosine Triphosphatase Rac2 in T Helper 1 Cell Differentiation. <i>Science</i> , 2000, 288, 2219-2222.	6.0	151
38	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. <i>Blood</i> , 2017, 129, 3362-3370.	0.6	150
39	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. <i>Blood</i> , 2016, 128, 1382-1395.	0.6	148
40	Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 119-129.	15.2	147
41	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019, 134, 111-122.	0.6	145
42	A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. <i>Blood</i> , 2008, 112, 5193-5201.	0.6	141
43	Genetic Influences Determining Progenitor Cell Mobilization and Leukocytosis Induced by Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1997, 89, 2736-2744.	0.6	140
44	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. <i>Nature Communications</i> , 2019, 10, 2385.	5.8	139
45	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17961-17966.	3.3	137
46	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , 2020, 44, 100672.	2.8	135
47	Targeting BCL2 for the Treatment of Lymphoid Malignancies. <i>Seminars in Hematology</i> , 2014, 51, 219-227.	1.8	130
48	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. <i>Blood</i> , 2016, 128, 1834-1844.	0.6	127
49	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	3.2	127
50	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 905-917.	3.3	126
51	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. <i>Leukemia</i> , 2018, 32, 303-312.	3.3	123
52	Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. <i>Leukemia</i> , 2014, 28, 2213-2221.	3.3	122
53	Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1 $\beta$ . <i>Journal of Experimental Medicine</i> , 2015, 212, 927-938.	4.2	120
54	Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11398-11403.	3.3	119

#	ARTICLE	IF	CITATIONS
55	The Rac2 Guanosine Triphosphatase Regulates B Lymphocyte Antigen Receptor Responses and Chemotaxis and Is Required for Establishment of B-1a and Marginal Zone B Lymphocytes. <i>Journal of Immunology</i> , 2002, 168, 3376-3386.	0.4	115
56	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. <i>Blood</i> , 2020, 135, 773-777.	0.6	115
57	Targeting BCL-2-like Proteins to Kill Cancer Cells. <i>Trends in Cancer</i> , 2016, 2, 443-460.	3.8	114
58	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3506-3517.	0.8	112
59	The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs. <i>Molecular Pharmacology</i> , 2010, 77, 483-494.	1.0	111
60	A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1406-1415.	0.6	111
61	Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. <i>Blood</i> , 2015, 125, 2649-2655.	0.6	107
62	Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 89-98.	2.3	107
63	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 354-369.	7.7	104
64	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. <i>PLoS Pathogens</i> , 2010, 6, e1001236.	2.1	99
65	Mouse loci for malaria-induced mortality and the control of parasitaemia. <i>Nature Genetics</i> , 1997, 17, 380-381.	9.4	98
66	Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13135-13140.	3.3	98
67	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 2034-2041.	3.3	91
68	GFI1B mutation causes a bleeding disorder with abnormal platelet function. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2039-2047.	1.9	91
69	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. <i>Blood</i> , 2018, 132, 1526-1534.	0.6	90
70	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood</i> , 2015, 126, 832-832.	0.6	90
71	Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. <i>Genome Biology</i> , 2021, 22, 310.	3.8	83
72	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20 <sup>+</sup> lymphoid malignancies. <i>British Journal of Haematology</i> , 2015, 170, 669-678.	1.2	80

#	ARTICLE	IF	CITATIONS
73	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. <i>Leukemia</i> , 2014, 28, 1207-1215.	3.3	79
74	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. <i>Blood</i> , 2020, 136, 2027-2037.	0.6	78
75	BCL2 and MCL1 inhibitors for hematologic malignancies. <i>Blood</i> , 2021, 138, 1120-1136.	0.6	78
76	Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16442-16447.	3.3	76
77	Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival. <i>Blood</i> , 2012, 119, 5850-5858.	0.6	76
78	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. <i>Blood</i> , 2021, 137, 2721-2735.	0.6	75
79	The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. <i>Blood</i> , 2005, 105, 3512-3520.	0.6	74
80	Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. <i>Blood</i> , 2007, 109, 2380-2388.	0.6	73
81	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. <i>British Journal of Haematology</i> , 2010, 150, 39-45.	1.2	72
82	Regulation of interleukin-12 by interferon-3 is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. <i>EMBO Reports</i> , 2010, 11, 640-646.	2.0	72
83	Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. <i>Stem Cells</i> , 1995, 13, 512-516.	1.4	68
84	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. <i>Blood</i> , 2020, 135, 2266-2270.	0.6	67
85	Therapeutic development and current uses of BCL-2 inhibition. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 1-9.	0.9	66
86	The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. <i>Annals of Hematology</i> , 2006, 86, 101-105.	0.8	63
87	Cytokine Production and Function in c-mpl-Deficient Mice: No Physiologic Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production. <i>Blood</i> , 1998, 91, 2745-2752.	0.6	62
88	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	61
89	A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 254-254.	0.6	61
90	The equivalents of human blood and spleen dendritic cell subtypes can be generated in vitro from human CD34+ stem cells in the presence of fms-like tyrosine kinase 3 ligand and thrombopoietin. <i>Cellular and Molecular Immunology</i> , 2012, 9, 446-454.	4.8	59

#	ARTICLE	IF	CITATIONS
91	Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation, 2001, 28, 101-103.	1.3	58
92	The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood, 2007, 110, 1466-1474.	0.6	57
93	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 4527-4533.	3.2	56
94	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia, 2018, 32, 1034-1037.	3.3	56
95	Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. Blood, 2011, 118, 282-282.	0.6	54
96	Rac2-deficient mice display perturbed T cell distribution and chemotaxis, but only minor abnormalities in TH 1 responses. Immunology and Cell Biology, 2002, 80, 231-240.	1.0	52
97	Absence of Suppressor of Cytokine Signalling 3 Reduces Self-Renewal and Promotes Differentiation in Murine Embryonic Stem Cells. Stem Cells, 2006, 24, 604-614.	1.4	51
98	Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood, 2009, 113, 4819-4820.	0.6	51
99	A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2005, 11, 5504-5514.	3.2	50
100	First-in Man, Phase 1 Study of CSL362 (Anti-IL3R $\alpha$ / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. Blood, 2014, 124, 120-120.	0.6	50
101	Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Internal Medicine Journal, 2004, 34, 192-200.	0.5	46
102	Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16333-16338.	3.3	45
103	Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2599-2604.	3.3	43
104	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death and Disease, 2012, 3, e409-e409.	2.7	42
105	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Advances, 2022, 6, 1296-1308.	2.5	42
106	IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunology and Cell Biology, 2012, 90, 124-129.	1.0	41
107	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF. Biology of Blood and Marrow Transplantation, 2006, 12, 603-607.	2.0	40
108	Neutrophils Require SHP1 To Regulate IL-1 $\beta$ Production and Prevent Inflammatory Skin Disease. Journal of Immunology, 2011, 186, 1131-1139.	0.4	40

#	ARTICLE	IF	CITATIONS
109	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. <i>Blood Advances</i> , 2021, 5, 4054-4058.	2.5	39
110	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021, 27, 4690-4695.	3.2	38
111	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. <i>Blood</i> , 2015, 126, 830-830.	0.6	38
112	SOCS3 regulates graft-versus-host disease. <i>Blood</i> , 2010, 116, 287-296.	0.6	37
113	Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16625-16630.	3.3	37
114	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e188-e191.	1.2	37
115	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. <i>Haematologica</i> , 2020, 105, e76-e79.	1.7	37
116	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. <i>Pathology</i> , 2011, 43, 525-535.	0.3	36
117	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <i>Blood Advances</i> , 2020, 4, 165-173.	2.5	34
118	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. <i>Blood</i> , 2022, 139, 1198-1207.	0.6	34
119	Studies of the Mpl Thrombopoietin Receptor through Gene Disruption and Activation. <i>Stem Cells</i> , 1996, 14, 124-132.	1.4	33
120	Dok-related protein negatively regulates T cell development via its RasGTPase-activating protein and Nck docking sites. <i>Journal of Cell Biology</i> , 2002, 158, 115-125.	2.3	33
121	Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation. <i>Nature Immunology</i> , 2020, 21, 54-64.	7.0	33
122	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. <i>Blood</i> , 2019, 134, 170-170.	0.6	33
123	Immune thrombocytopenia complicating pulmonary tuberculosis: case report and investigation of mechanisms. <i>Thorax</i> , 1992, 47, 396-397.	2.7	32
124	The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients. <i>Blood</i> , 2013, 122, 1789-1789.	0.6	32
125	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 325-325.	0.6	32
126	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013, 122, 108-108.	0.6	31



#	ARTICLE	IF	CITATIONS
127	A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 157-163.	1.3	29
128	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. <i>Leukemia</i> , 2016, 30, 1531-1541.	3.3	29
129	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. <i>Cell Death and Differentiation</i> , 2020, 27, 2217-2233.	5.0	29
130	Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. <i>Experimental Hematology</i> , 2008, 36, 786-798.	0.2	28
131	Fas regulates neutrophil lifespan during viral and bacterial infection. <i>Journal of Leukocyte Biology</i> , 2015, 97, 321-326.	1.5	28
132	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. <i>Blood Advances</i> , 2020, 4, 2762-2767.	2.5	28
133	Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. <i>Blood</i> , 2022, 140, 2127-2141.	0.6	28
134	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 714-722.	3.2	27
135	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. <i>Blood</i> , 2021, 138, 836-846.	0.6	27
136	Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. <i>Experimental Hematology</i> , 2002, 30, 1248-1256.	0.2	25
137	A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide Reduced Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 560-567.	2.0	24
138	Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells. <i>PLoS ONE</i> , 2016, 11, e0162111.	1.1	24
139	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , 2019, 134, 756-756.	0.6	24
140	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. <i>American Journal of Human Genetics</i> , 2022, 109, 953-960.	2.6	23
141	Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 435-442.	2.0	22
142	Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3525-3527.	0.8	22
143	First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).. <i>Blood</i> , 2006, 108, 58-58.	0.6	22
144	A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 447-453.	1.3	20

#	ARTICLE	IF	CITATIONS
145	Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , 2006, 37, 923-928.	1.3	20
146	Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). <i>Blood</i> , 2013, 121, 1479-1481.	0.6	20
147	Current challenges and novel treatment strategies in double hit lymphomas. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 52-64.	1.1	20
148	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 975-975.	0.6	20
149	Management of systemic <sc>AL</sc> amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 371-382.	0.5	19
150	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.5	19
151	Venetoclax in Lymphoid Malignancies: New Insights, More to Learn. <i>Cancer Cell</i> , 2019, 36, 341-343.	7.7	19
152	A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e53-e54.	0.2	19
153	Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2. <i>Growth Factors</i> , 2009, 27, 384-393.	0.5	18
154	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. <i>Blood</i> , 2012, 120, 304-304.	0.6	18
155	Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. <i>Bone Marrow Transplantation</i> , 2008, 41, 651-658.	1.3	17
156	Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 274-279.	0.8	17
157	Venetoclax: a primer. <i>Blood Advances</i> , 2017, 1, 467-467.	2.5	17
158	Identification of a genetic locus modulating splenomegaly induced by granulocyte colony-stimulating factor in mice. <i>Leukemia</i> , 2000, 14, 657-661.	3.3	16
159	Successful Allogeneic Stem Cell Transplant after Invasive Pulmonary Zygomycosis. <i>Leukemia and Lymphoma</i> , 2002, 43, 437-439.	0.6	16
160	Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2016, 46, 737-741.	0.5	16
161	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. <i>Oncogene</i> , 2020, 39, 2009-2023.	2.6	16
162	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011, 118, 3849-3849.	0.6	16

#	ARTICLE	IF	CITATIONS
163	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. <i>Blood</i> , 2015, 126, 3038-3038.	0.6	16
164	Single-cell sequencing demonstrates complex resistance landscape in $\text{A}^{\text{CLL}}$ and MCL treated with BTK and BCL2 inhibitors. <i>Blood Advances</i> , 2022, 6, 503-508.	2.5	16
165	Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. <i>Pathology</i> , 2006, 38, 336-342.	0.3	14
166	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1678-1685.	0.8	14
167	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020, 4, 4849-4859.	2.5	14
168	Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study). <i>Blood</i> , 2018, 132, 333-333.	0.6	14
169	Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNF $\alpha$ . <i>Growth Factors</i> , 2007, 25, 319-328.	0.5	13
170	Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1448-1450.	0.6	13
171	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia & Australian Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 94-105.	0.5	13
172	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-8.	0.6	13
173	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. <i>Blood</i> , 2012, 120, 178-178.	0.6	13
174	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. <i>Blood</i> , 2015, 126, LBA-6-LBA-6.	0.6	13
175	Mini $\text{ALLO}$ ™ for haematological malignancies: an alternative to conventional myeloablative marrow transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 308-314.	0.5	12
176	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3230-3230.	0.6	12
177	More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. <i>Blood</i> , 2006, 107, 1733-1735.	0.6	10
178	Validating the Allogeneic Stem Cell Transplantation Disease Risk Index. <i>Transplantation</i> , 2015, 99, 128-132.	0.5	10
179	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2017, 47, 35-49.	0.5	10
180	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. <i>Blood</i> , 2013, 122, 1304-1304.	0.6	10

#	ARTICLE	IF	CITATIONS
181	Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2939-2939.	0.6	10
182	Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. <i>British Journal of Haematology</i> , 2002, 119, 204-211.	1.2	9
183	Perturbed thymopoiesis in vitro in the absence of suppressor of cytokine signalling 1 and 3. <i>Molecular Immunology</i> , 2008, 45, 2888-2896.	1.0	9
184	A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 645-650.	1.3	8
185	Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. <i>Lancet Haematology</i> , 2014, 1, e112-e119.	2.2	8
186	Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. <i>International Journal of Laboratory Hematology</i> , 2003, 25, 119-125.	0.2	7
187	Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma. <i>Internal Medicine Journal</i> , 2004, 34, 431-434.	0.5	7
188	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4395-4395.	0.6	7
189	Towards a Four-Dimensional View of Neutrophils. <i>Methods in Molecular Biology</i> , 2012, 844, 87-99.	0.4	6
190	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 335-343.	0.5	6
191	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , 2018, 48, 786-794.	0.5	6
192	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, LBA-7-LBA-7.	0.6	6
193	Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip. <i>Blood</i> , 2004, 104, 2253-2253.	0.6	6
194	Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2033-2033.	0.6	6
195	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. <i>Blood</i> , 2019, 134, 3999-3999.	0.6	6
196	Bortezomib: Putting mantle cell lymphoma on death row. <i>Leukemia and Lymphoma</i> , 2008, 49, 657-658.	0.6	5
197	Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?. <i>Cancer Discovery</i> , 2019, 9, 998-1000.	7.7	5
198	Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. <i>Blood</i> , 2018, 132, 183-183.	0.6	5

#	ARTICLE	IF	CITATIONS
199	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. <i>Blood</i> , 2019, 134, 462-462.	0.6	5
200	Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study. <i>Blood</i> , 2013, 122, 537-537.	0.6	5
201	Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1994, 24, 541-546.	0.5	4
202	BH3-mimetics – the solution to chemoresistance?. <i>Leukemia and Lymphoma</i> , 2009, 50, 1069-1072.	0.6	4
203	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 5222-5234.	3.2	4
204	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	0.6	4
205	The Diagnosis of Abdominal Aortic Aneurysms <sup>1</sup> . <i>ANZ Journal of Surgery</i> , 1974, 44, 360-362.	0.3	3
206	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. <i>EJHaem</i> , 2021, 2, 266-271.	0.4	3
207	The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16). <i>Blood</i> , 2020, 136, 16-18.	0.6	3
208	Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies. <i>Blood</i> , 2010, 116, 3943-3943.	0.6	3
209	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. <i>Blood</i> , 2012, 120, 3923-3923.	0.6	3
210	Abnormal neutrophil phenotype and neutrophil FcR111 deficiency corrected by bone marrow transplantation. <i>Transfusion</i> , 2003, 35, 874-878.	0.8	2
211	BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 909-911.	0.6	2
212	Donald Metcalf (1929–2014). <i>Cell</i> , 2015, 160, 361-362.	13.5	2
213	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). <i>Leukemia and Lymphoma</i> , 2021, 62, 2981-2991.	0.6	2
214	High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 15-16.	0.6	2
215	BCL2 inhibition in double hit lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1928-1929.	0.6	1
216	Venetoclax for the treatment of mantle cell lymphoma. <i>Annals of Lymphoma</i> , 2019, 3, 4-4.	4.5	1

#	ARTICLE	IF	CITATIONS
217	Changing of the guard – the old and the new. <i>Blood</i> , 2020, 135, 1-1.	0.6	1
218	Targeting apoptotic pathways to treat lymphoid malignancies. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2016, 57, 2054-2058.	0.5	1
219	All-trans retinoic acid – chemotherapy interactions in acute promyelocytic leukaemia. <i>Australian and New Zealand Journal of Medicine</i> , 1992, 22, 704-704.	0.5	0
220	Optimal Regimens for the Mobilization and Collection of Peripheral Blood Progenitor Cells from Normal Donors. <i>Leukemia and Lymphoma</i> , 1997, 27, 77-82.	0.6	0
221	Reply to M. Cavo. <i>Journal of Clinical Oncology</i> , 2009, 27, e188-e188.	0.8	0
222	BCL2 Inhibitors: Insights into Resistance. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 23-43.	0.1	0
223	Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies. <i>Blood</i> , 2021, 138, 1089-1089.	0.6	0
224	Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype.. <i>Blood</i> , 2004, 104, 2262-2262.	0.6	0
225	Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF.. <i>Blood</i> , 2005, 106, 1970-1970.	0.6	0
226	A Pilot Study To Explore the Tolerability and Efficacy of Thalidomide Containing Regimens To Reduce Tumour Cell Load Prior to HSC in Multiple Myeloma and the Feasibility of Harvesting HSC Following Thalidomide Containing Regimens.. <i>Blood</i> , 2005, 106, 5162-5162.	0.6	0
227	Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 5115-5115.	0.6	0
228	Complete Remission on 18F-FDG-PET Prior to Autologous Stem Cell Transplantation Predicts Superior Event Free Survival of Patients with Relapsed or Refractory Hodgkin Lymphoma.. <i>Blood</i> , 2008, 112, 2188-2188.	0.6	0
229	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. <i>Journal of Cell Biology</i> , 2011, 194, i12-i12.	2.3	0
230	Necroptotic Death Of RIPK1-Deficient HSC Compromises Hematopoiesis. <i>Blood</i> , 2013, 122, 218-218.	0.6	0
231	Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations. <i>Blood</i> , 2013, 122, 2143-2143.	0.6	0
232	Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments. <i>Blood</i> , 2014, 124, 2103-2103.	0.6	0
233	Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1 $\beta$ . <i>Journal of Cell Biology</i> , 2015, 209, 2095-2104.	2.3	0
234	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. <i>Blood</i> , 2016, 128, 338-338.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Abstract 1366:MBD4guards against DNA damage from methylcytosine deamination. , 2018, , .		0
236	Acute leukaemia in Australia: outcomes have improved, but there is still much to do. Medical Journal of Australia, 2022, 216, 289-290.	0.8	0